Agammaglobulinemia clinical trials
The registry lists 38 studies for Agammaglobulinemia across more than 10 countries. 10 are recruiting or about to start. 13 of them are mainly about Agammaglobulinemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Severe combined immunodeficiency due to adenosine deaminase deficiency too: 67 studies, 14 open.
Get an email when these change. Save the Agammaglobulinemia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
CSL Behring (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Kedrion S.p.A. (3) · Octapharma (2) · Grifols Therapeutics LLC (2) · M.D. Anderson Cancer Center (2) · Prothya Biosolutions (1) · BriovaRx Infusion Services (1)
What is being tested here
Drugs under test in Agammaglobulinemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4, phase 3 first
- Dec 2026Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) · Phase 3 · Kedrion S.p.A.
- Apr 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension · Phase 3 · Monash University
- Dec 2026IVIG vs SCIG in CIDP · Rutgers, The State University of New Jersey
- Dec 2026Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? · Insel Gruppe AG, University Hospital Bern
Who these studies take
Of the 9 Agammaglobulinemia studies recruiting now, 6 (67%) set no upper age limit and 2 (22%) stop at 75 or younger. 2 (22%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (22%) | 2 (22%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 9 (100%) | 9 (100%) |
| 75 | 7 (78%) | 7 (78%) |
| 85 | 7 (78%) | 7 (78%) |
Across all 38 studies, recruiting or not: 45% stop at 75 or younger and 13% at 65; 55% take children; 0% are for women only and 3% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Studies
Recruiting first, then most recently updated. Showing 38 of 38. search them.
- A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaRecruitingNCT05645107Phase 38 countries
- Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)RecruitingNCT000012441 country
- Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent InfectionsRecruitingNCT07220915Phase 37 countries
- Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationNCT07775313Phase 1/21 country
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingNCT07648264Phase 311 countries
- Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and HypogammaglobulinemiaRecruitingNCT06976476Phase 21 country
- Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?RecruitingNCT053577811 country
- V-IMMUNE: A Novel Immunoglobulin Therapy for ImmunodeficiencyRecruitingNCT06954441Phase 31 country
- IVIG vs SCIG in CIDPRecruitingNCT05584631Phase 11 country
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or ExtensionRecruitingNCT05678621Phase 2/31 country
- Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)CompletedNCT04502030Phase 312 countries
- A Phase I Study of Mozobil in the Treatment of Patients With WHIMSCompletedNCT00967785Phase 1/21 country
- Plerixafor Versus G-CSF in the Treatment of People With WHIM SyndromeCompletedNCT02231879Phase 2/31 country
- Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)Active, not recruitingNCT04944979Phase 36 countries
- Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID PatientsCompletedNCT03961009Phase 31 country
- Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)CompletedNCT00161993Phase 22 countries
- Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)CompletedNCT01581593Phase 32 countries
- Rituximab-Induced Hypogammaglobulinemia in Multiple SclerosisStatus unknownNCT042837471 country
- Immunodeficiency in MSStatus unknownNCT044479371 country
- Personalized Immunotherapeutic for Antibiotic-resistant InfectionCompletedNCT02508584Early Phase 11 country
- Oral Colostrum and Its Effect on Immune SystemStatus unknownNCT03578341Phase 31 country
- Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)TerminatedNCT018839211 country
- Subcutaneous Ig in Allogeneic Stem Cell Transplant RecipientsCompletedNCT03401268Not applicable1 country
- Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01002755Phase 21 country
- Intravenous Immunoglobulin (IVIG) in Lung TransplantationCompletedNCT00115778Phase 21 country
- A Retrospective and Prospective Natural History Study of Patients With WHIM SyndromeWithdrawnNCT03087370
- Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01924169Phase 21 country
- Post-bypass Prophylactic IVIG in Infants and NeonatesCompletedNCT02043379Not applicable1 country
- Investigation of Immune Disorders and DeficienciesStatus unknownNCT019817851 country
- Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary ImmunodeficiencyCompletedNCT00520494Phase 44 countries
- Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.CompletedNCT00278954Phase 31 country
- Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00322556Phase 31 country
- Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168025Phase 3
- Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168012Phase 3
- Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant RecipientsCompletedNCT00137748Phase 2/31 country
- Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsCompletedNCT00220766Phase 32 countries
- Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous ImmunoglobulinCompletedNCT00661401Not applicable1 country
- Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia PatientsCompletedNCT00138697Phase 2/31 country